Gender in cardiac resynchronisation therapy

Tatiana N. Enina¹*, Vadim A. Kuznetsov³, Anna M. Soldatova¹, Tatiana I. Petelina¹, Dmitriy V. Krinochkin¹, Alexander Yu. Rychkov¹, Olga Yu. Nochrina²

¹Scientific Researcher in Instrumental Laboratory of Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia
²Director of Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia

Abstract

Introduction: Gender differences in cardiac resynchronisation therapy (CRT) response are not clear enough. This study aimed to assess gender influence on systemic inflammation, neurohormonal activation, fibrosis in patients with congestive heart failure (CHF) and CRT.

Methods: We compared group I (61 men) and group II (16 women) of patients undergoing CRT. Plasma levels of Nt-proBNP, interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor alpha (TNF-α), C-reactive protein, galectin-3 (Gal-3), metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase 1 and 4 (TIMP-1, TIMP-4), ratio MMP-9/TIMP-1, MMP-9/TIMP-4 were measured. According to dynamics of left ventricular end-systolic volume patients were classified into non-responders, responders, super-responders.

Results: Women more likely had left bundle branch block (81.3 vs 47.5%, P = 0.016), were more super-responders (66.7 vs 30.5%). Both groups showed decrease of IL-6 (P < 0.05), TNF-α (P < 0.001; P < 0.05), NT-proBNP (P < 0.001; P < 0.05), Gal-3 (P < 0.05). In women there was decrease of IL-6 by 44.4 vs 23.5% in men (P = 0.029), TNF-α by 41.4 vs 30.9%, NT-proBNP by 73.3 vs 46% (P < 0.002), Gal-3 by 82.3 vs 64.9% (P < 0.05). Group I also showed decrease of IL-10 by 34.2% (P < 0.05). Group dynamics of TIMP-1 was opposite: men showed tendency to reduction of TIMP-1 (P = 0.054), women showed increase of TIMP-1 (P < 0.05). Besides, men showed decrease of MMP-9 (P < 0.05) and ratio MMP-9/TIMP-4 (P < 0.05).

Conclusion: The best response to CRT is associated with female gender explained by greater decrease of neurohormonal activation, systemic inflammation and fibrosis. The revealed opposite dynamics of TIMP-1 in the groups can demonstrate the existence of gender features of matrix metalloproteinase system activity and their tissue inhibitors.

Introduction

Congestive heart failure (CHF) remains highly fatal pathology for men and women.¹ A modern method for treatment of CHF is cardiac resynchronisation therapy (CRT) which effects lead to remodeling of heart, reduction of symptoms, decrease in hospitalization and mortality.²-⁴ Earlier more efficiency of CRT was shown in women.⁵-⁸ Among the possible reasons causing gender specifics of remodeling of heart in women, smaller sizes of heart and duration of QRS, higher percent of β-blockers, digoxin, antagonists of an aldosterone,³ higher dynamics of remodeling of heart,⁹,10,12 higher percent of biventricular stimulation,¹⁰,10,11 higher frequency of dilated cardiomyopathy⁸,12 and complete left bundle branch block (CLBBB), higher frequency of atrial fibrillation in men were noted.⁵ However, mechanisms of higher CRT efficiency in women are still not clear. It is complicated owing to the low percent of the women included in researches on CRT - about 20%.⁸,11-15 The researches COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) and CARE-HF (Cardiac Resynchronization-Heart Failure) did not confirm gender distinctions of CRT efficiency.¹⁶,¹⁷ An important role in CHF genesis is played by the immune inflammation.¹⁸ The cytokine system imbalance can result in myocardium remodeling because of matrix metalloproteinase (MMPs) activation causing collagen degradation and remodeling of the extracellular cardiac matrix (ECM),¹⁹ development of myocardium fibrosis,²⁰,²¹ CRT influence on the processes of inflammation²²-²⁵

*Corresponding Author: Tatiana N. Enina, Email: yenina@cardio.tmn.ru

© 2018 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
remodeling of ECM,26-28 fiber formation is known.29,30 However, influence of these processes on gender specifics of myocardium remodeling after CRT is not studied. This study aimed to study gender features of CRT efficiency, determine its influence on dynamics of the immune inflammation, neurohormonal activation markers and fibrosis in patients with CHF.

Materials and Methods
Initially and in the term of the best response to CRT evaluated by the maximum decrease in left ventricular end-systolic volume (LVESV). 77 patients with CHF of ischemic (65%) and non-ischemic genesis from the Register of the performed CRT operations in the Tyumen Cardiology Research Center41 were examined. Patients signed the informed consent to comprehensive examination and intervention. Two groups were formed on the gender basis: I group (n = 61; 79%) men, II group (n = 16; 21%) - women. CRT-D devices were implanted in 66.1% of men and in 38.9% of women (p=0.039). The clinical characteristic of groups is presented in Table 1. The groups were comparable by the main parameters, however, women more often had CLBBB (81.3% vs 47.5%, P=0.016), and men – atrial fibrillation (39% vs 17%, P=0.017). No differences in therapy in the groups were noted.

The functional class of heart failure was defined taking into account 6-minute walking test. Echocardiography (EchoCG) was performed in dynamics using IE33 (Philips). Plasma NT-proBNP levels, interleukin (IL) - 1b, IL-6, IL-10, FNO-α, galectin-3 (Gal-3), matrix metalloproteinase 9 (MMP-9), tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-4) were analyzed by the method of solid-phase chemiluminescent immunoassay (a “sandwich-method”) on the IMMULITE 1000 analyzer (Siemens Diagnostics, the USA). Coefficients of MMP-9/TIMP-1, MMP-9/TIMP-4 were calculated. Determination of highly sensitive C-reactive protein in blood serum was carried out by the immune turbidimetric method using analytical PROTEIN C- REACTIVE sets (BioSystems, Spain) on the Clima MC-15 analyzer (Spain).

In normal distribution of the data, the results are presented as a mean value ± standard deviation, in abnormal distribution – as a median and interquartile range [25%, 75%]. Quantitative data were compared by t-Student criterion, in abnormal distribution - in case of intergroup comparison Mann-Whitney U-criterion was used, in case of intra group - Wilcoxon criterion. Qualitative variables compared by criterion χ². P<0.05 was considered to be significant.

Results
In both groups, there was a positive dynamics of echocardiographic parameters after CRT (Table 2). However, the rate of change of some parameters was more significant in the group of women (Table 3). In group II more super-responders (62.5 vs 32.8%) were registered, less nonresponders (18.8 vs 36.1%) and responders (18.8 vs 31.1%) (P=0.03) (Table 1). Significant decrease of IL-6 (P<0.05), TNF-α (P<0.001 in group I; P<0.05 in group II) (Table 4), NT-proBNP (P=0.001; P<0.05), Gal-3 (P<0.05) was observed in both groups (Table 5). However, in group II dynamics of biomarkers was more expressed: IL-6 decrease by 44.4 vs 23.5% in group I (P=0.029), TNF-α by 41.4 vs 30.9%, NT-proBNP by 73.3 vs 46% (P=0.002), Gal-3 by 82.3 vs 64.9%. In group I significant decrease of IL-10 by 34.2% (P<0.05), MMP-9 (P<0.05)

### Table 1. Clinical characteristic of patients

| Parameter                  | Group I men (n=61) | Group II women (n=16) | P       |
|----------------------------|--------------------|-----------------------|---------|
| Time of the best response to CRT, month | 14.0 [4.5;32.0] | 16.0 [10.0;30.0] | NS      |
| Age (y)                    | 55.7±7.8           | 56.3±10.2 | NS      |
| CAD (%)                    | 42 (68.9)          | 8 (50)     | NS      |
| PMI (%)                    | 25 (41.0)          | 3 (18.8)   | NS      |
| CABG (%)                   | 8 (13.1)           | 0          | 0.099   |
| PCI (%)                    | 16 (26.2)          | 2 (12.5)   | NS      |
| FC II (%)                  | 24 (39.3)          | 7 (43.8)   | NS      |
| FC III (%)                 | 31 (50.8)          | 6 (37.5)   | NS      |
| FC IV (%)                  | 6 (9.8)            | 3 (18.8)   | NS      |
| AH (%)                     | 46 (75.4)          | 13 (81.2)  | NS      |
| DM (%)                     | 9 (14.8)           | 3 (18.8)   | NS      |
| Obesity (%)                | 41 (67.2)          | 13 (81.3)  | NS      |
| AF (%)                     | 23 (39)            | 3 (17)     | 0.017   |
| RFA AV-connections (%)     | 25 (41.0)          | 3 (18.8)   | NS      |
| CLBBB (%)                  | 29 (47.5%)         | 13 (81.3%) | 0.016   |
| Nitrates (%)               | 30.5               | 22.2       | NS      |
| Ca channel blockers (%)    | 20.3               | 27.8       | NS      |
| Digoxin (%)                | 61.0               | 38.9       | 0.098   |
| Statins (%)                | 79.7               | 72.2       | NS      |
| β-blockers (%)             | 100.0              | 100.0      | NS      |
| Diuretics (%)              | 98.3               | 100.0      | NS      |
| MCRA (%)                   | 100.0              | 100.0      | NS      |
| Warfarin (%)               | 50.8               | 27.8       | NS      |
| ACEI (%)                   | 93.2               | 77.8       | 0.060   |
| Antiarrhythmics (%)        | 47.5               | 50.0       | NS      |
| Response to CRT            | 0.003              |            |         |
| Non-responders (%)         | 22 (36.1)          | 3 (18.8)   |         |
| Responders (%)             | 19 (31.1)          | 3 (18.8)   |         |
| Super-responders (%)       | 20 (32.8)          | 10 (62.4)  |         |

CRT, cardiac resynchronisation therapy; CAD, coronary artery disease; PMI, previous myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; FC, functional class due to NYHA classification; AH, arterial hypertension; DM, diabetes mellitus; AF, atrial fibrillation; RFA AV-connection, radiofrequency ablation of atroventricular connection; CLBBB, complete left bundle branch block; MCRA, mineralocorticoid receptor antagonists; ACEI, angiotensin-converting enzyme inhibitors; NS, not significant (P > 0.05).
Gender in cardiac resynchronisation therapy

Table 2. EchocG parameters in groups

| Parameter         | Group I men (n=61) | Group II women (n=16) | P between groups |
|-------------------|--------------------|-----------------------|------------------|
| AO (mm)           | 35.2±3.0           | 31.7±3.0              | <0.001           |
| LA (mm)           | Initially 51.2±6.5  | 47.7±6.3              | 0.049            |
|                  | In dynamics 48.8±1±5.8* | 43.5±7.6*             | 0.015            |
| RA (ml)           | Initially 89.2±32.4 | 60.6±33.2             | 0.006            |
|                  | In dynamics 76.8±31.4* | 54.6±30.1*           | 0.084            |
| RV (mm)           | Initially 31.2±4.0  | 28.2±4.4              | 0.013            |
|                  | In dynamics 29.6±3.9* | 26.2±2.7*             | <0.001           |
| LVEDD (mm)        | Initially 55.4±7.0  | 52.1±5.8              | 0.064            |
|                  | In dynamics 51.1±9.3* | 44.4±9.4*           | 0.006            |
| LVEDD (mm)        | Initially 65.8±7.2  | 62.6±6.0              | 0.062            |
|                  | In dynamics 62.5±7.6* | 55.8±3.8*              | <0.001           |
| LVESV (ml)        | Initially 154.5±46.5 | 135.8±35.0             | 0.075            |
|                  | In dynamics 117.6±49.4* | 78.7±26.1*         | <0.002           |
| LVEDV (ml)        | Initially 225.4±56.1 | 200.4±42.4             | 0.050            |
|                  | In dynamics 190.5±59.2* | 142.8±37.3*        | <0.001           |
| LVEF (%)          | Initially 32.1±16.3 | 32.8±5.3              | NS               |
|                  | In dynamics 39.6±8.8* | 45.5±7.3*              | 0.008            |
| Dysssynergia LV (%) | 19.0±24.0           | 2.2±6.7               | 0.098            |

* P < 0.001 in the group; * P < 0.05 in the group; NS, not significant; LA, left atrium; RA - right atrium; RV, right ventricle; LV, left ventricle; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction.

Table 3. Degree of EchocG changes in the groups

| Parameter         | Group I men (n=61) | Group II women (n=16) | P between groups |
|-------------------|--------------------|-----------------------|------------------|
| ∆LA (mm)          | -2.4±3.9           | -4.2±3.1              | 0.057            |
| ∆RA (mm)          | -14.9±21.5         | -22.8±19.9            | NS               |
| ∆RV (ml)          | -1.6±2.9           | -2.0±3.0              | NS               |
| ∆LVEDD (mm)       | -4.8±4.7           | -7.3±4.6              | 0.097            |
| ∆LVEDV (mm)       | -3.3±4.1           | -6.8±4.3              | 0.005            |
| ∆LVESV (mm)       | -35.0±35.2         | -57.6±40.7            | 0.043            |
| ∆LVEF (%)         | -37.0±28.8         | -57.0±33.1            | 0.035            |

Table 4. Inflammation markers in the groups

| Parameter         | Group I men (n=61) | Group II women (n=16) | P between groups |
|-------------------|--------------------|-----------------------|------------------|
| IL-1β (pg/ml)     | 4.1[3.4;4.8]       | 4.1[3.8;4.3]          | NS               |
| IL-1β in dynamics (pg/ml) | 3.4[3.1;4.3]       | 4.4[3.2;5.0]          | NS               |
| IL-6 (pg/ml)      | 3.4[2.6;6.6]       | 2.7[2.5;3.9]          | NS               |
| IL-6 in dynamics (pg/ml) | 2.6[1.6;4.6]#       | 1.5[1.2;3.0]#         | 0.029            |
| IL-10 (pg/ml)     | 4.1[2.7;5.0]       | 3.0[1.7;5.0]          | NS               |
| IL-10 in dynamics (pg/ml) | 2.7[2.1;4.1]#       | 2.5[1.8;3.0]          | NS               |
| TNF-α (pg/ml)     | 9.4[8.0;11.2]      | 9.9[6.9;11.0]         | NS               |
| TNF-α in dynamics (pg/ml) | 6.5[4.9;9.0]#       | 5.8[4.5;8.6]#         | NS               |
| CRP (mg/ml)       | 4.8[2.4;9.1]       | 4.1[2.0;6.6]          | NS               |
| CRP in dynamics (mg/ml) | 3.1[1.6;6.7]       | 2.1[0.8;6.6]          | NS               |

# P < 0.05; * P < 0.001; IL - interleukin; TNF-α - tumor necrosis factor alpha; CRP - C-reactive protein

and MMP-9/TIMP-4 was registered (P < 0.05). Opposite dynamics of TIMP-1 was found in both groups: in group I – tendency to TIMP-1 decrease (P = 0.054), in group II – significant TIMP-1 increase (P < 0.05) (Table 5).

Discussion

Association of positive reaction to CRT with the female gender can be due to significant decrease in neurohumoral activity and immune inflammation. NT-proBNP significant decrease in patients with the favorable reaction to CRT was already described.23-35 Both initially and in dynamics lower concentrations of NT-proBNP were found in group II, which is probably connected with the smaller size of cardiac cavities in women, and also with larger dynamics of the return remodeling after CRT (Tables 2 and 3).

Association of CRT efficiency with the activity of immune inflammation was described by a number of authors.23-25 Unlike our results, Boriani et al. in 3 months,36 Osmancik et al. in 6 months24 Seifert et al37 and Tarquini et al in 1 year of CRT34 did not reveal IL-6 and TNF-α dynamics. At the same time Orrego et al in 3 months of CRT noted significant TNF-α decrease.38 Rordorf et al33 showed TNF-α influence on remodeling of cardiac cavities after CRT. TNF-α is one of the main mediators of the immune response. Cardiomyocytes can induce TNF-α in myocardium wall tension (a diastolic stress), and the higher final diastolic pressure level in left ventricle, the higher amount of the produced cytokine.39 Significant decrease of cardiac cavities in group II can explain the possible mechanism of the more expressed TNF-α decrease. TNF-α, IL-6, IL-1β common property is their

J Cardiovasc Thorac Res, 2018, 10(4), 197-202 | 199
ability to exert negative inotropic effect. Naturally, the more expressed decrease of cytokine concentration in group is followed by higher dynamics of EchoCG and increase of left ventricular ejection fraction. The fixed terms of CRT efficiency assessment without considering its best efficiency according to LVESV dynamics, used in our work, can influence the discrepancy of results in studies. In the absence of differences IL-6 basic levels in groups, its dynamics was more expressed in group II. Development of LV diastolic dysfunction - responder was described only in responder.24,25 The higher percent of patients with the favorable reaction to CRT in group II is naturally followed by higher cytokine level decrease.

Immune inflammation is known to influence the processes of a fiber formation and remodeling of ECM. Gal-3 is a rather new marker of fibrosis, which increased concentration is followed by progressing diastolic dysfunction. The study of MADIT-CRT showed that the increased Gal-3 level is an independent predictor of an unfavourable outcome in patients with moderate CHF.26 However, CARE-HF studies showed that Gal-3 level changes after CRT.27 In BIOCRT study predictor ability of GAL-3 in the complex with NT-proBNP and sST2 was compared. The increased levels of all three studied biomarkers in the coronary sinus showed 95% specificity for the negative response to CRT. Our results confirm Gal-3 level decrease after CRT in the groups.

There are data on CRT influence on MMPs system activity and their tissue inhibitors (TIMPs) playing a key role in ECM remodeling.28,29 ECM modernization is in fact an adaptive process leading to changes of myocardium tensile properties, preservation of heart geometrical shape or formation of cardiac chambers new formation. MMPs and TIMPs both localized in the myocardium regulate synthesis and disintegration of ECM proteins, interfering with the development of disorders of systolic and diastolic functions. There are literature data on cytokine direct influence on the ECM catabolism activity by MMPs activation.30 The results of our study confirm CRT ability to exert modulating influence on ECM due to the decrease in MMP-9 and the ratio of MMP-9/TIMP-4 in the group of men. However, the revealed opposite dynamics of TIMP-1 levels in the groups may show the existence of gender specifics of ECM remodeling. Tolosana et al in 12 months of CRT in the group of non-responder noted higher levels of fibrosis markers (MMP-2 and TIMP-1), and TIMP-1 level ≥248 ng/mL was an independent predictor of non-responders to CRT with 71% of sensitivity and 72% of specificity.31 In the groups studied higher basic TIMP-1 levels were found, moreover in group II its significant increase in dynamics was registered. In spite of this 62.4% of women became super-responders, and 18.8% responders to CRT with 71% of sensitivity and 72% of specificity.31 Distinctions of response to CRT may be due to differences between men and women. Studying of sex hormones was not the task of the present research. However, cardioactive effects of sex hormones on physiological processes in myocardium may influence CRT outcomes. Literature describes ability of sex hormones to exert both anti-inflammatory effect,32,33 and cardioprotective action on ECM state.34,35 Further studies are necessary.

Thus, the best response to CRT is associated with women

### Table 5. NT-proBNP and markers of fibrosis in the groups

| Parameter                        | Group I men (n=61) | Group II women (n=16) | P Between groups |
|----------------------------------|--------------------|-----------------------|-----------------|
| NT-proBNP (pg/ml)                | 2134.5 [1010.3;4156.8] | 1154.0 [537.0;2485.5] | 0.003 |
| NT-proBNP in dynamics (pg/ml)    | 1153.0 [582.0;2285.5]** | 308.5 [237.0;568.3]* | 0.002 |
| Galectin-3 (ng/ml)               | 0.74 [0.28;12.3]   | 0.62 [0.14;11.1]      | NS              |
| Galectin-3 in dynamics (ng/ml)   | 0.26 [0.04;1.36]*  | 0.11 [0.04;0.31]*     | NS              |
| MMP-9 (ng/ml)                    | 157.9 [121.3;203.5] | 129.1 [83.5;303.5]    | NS              |
| MMP-9 in dynamics (ng/ml)        | 136.5 [113.6;157.4]*| 132.4 [88.4;153.0]    | NS              |
| TIMP-1 (ng/ml)                   | 471.5 [330.1;570.0] | 360.9 [271.9;405.4]   | 0.038 |
| TIMP-1 in dynamics (ng/ml)       | 413.8 [333.9;485.2]§| 410.6 [275.0;461.0]*  | NS              |
| TIMP-4 (ng/ml)                   | 2131.5 [1634.0;3252.2] | 2185.1 [1865.3;2611.7] | NS              |
| TIMP-4 in dynamics (ng/ml)       | 2516.4 [1808.5;3416.6] | 2549.3 [2116.9;3260.5] | NS              |
| MMP-9/TIMP-1 (U)                 | 0.34 [0.25;0.51]   | 0.38 [0.23;0.63]      | NS              |
| MMP-9/TIMP-1 in dynamics (U)     | 0.35 [0.25;0.49]   | 0.35 [0.26;0.47]      | NS              |
| MMP-9/TIMP-4 (U)                 | 0.07 [0.05;0.12]   | 0.06 [0.03;0.11]      | NS              |
| MMP-9/TIMP-4 in dynamics (U)     | 0.05 [0.03;0.07]*  | 0.05 [0.03;0.08]      | NS              |

Abbreviations: NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of matrix metalloproteinase.

- * P < 0.05; ** P = 0.001; § P = 0.054.
that is probably caused by a more marked decrease of system inflammation, neurohormonal activation, fibrosis. CRT probably exerts the modulating effect on ECM state by decrease of system inflammation which plays the leading role in heart remodeling. The revealed opposite dynamics of TIMP-1 in the groups can demonstrate the existence of gender features of matrix metalloproteinase system activity and their tissue inhibitors.

**Ethical approval**

This investigation has been approved by the Ethics Committee of the Tyumen Cardiology Research Center.

**Competing interests**

All authors declare no competing financial interests exist.

**References**

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002;347:1397-1402. doi: 10.1056/NEJMoa020265.
2. Kuznetsov VA, Vinogradova TO, Enina TN, Kolunin GV, Kharaets PV, Pavlov AV, et al. Impact of cardiac resynchronization therapy on survival in patients with ischemic and non-ischemic cardiomyopathy in clinical practice. *Ther Arch* 2012;84(5):52-6.
3. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J* 2013;34(29):2281-329. doi: 10.1093/europe/est206.
4. Rickard J, Michtalik H, Sharma R, Berger Z, Iyoha E, Green AR, et al. Use of Cardiac Resynchronization Therapy in the Medicare Population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
5. Zusterzeel R, Spatz ES, Curtis JP, Sanders WE, Selzman KA, Pica IL, et al. Cardiac Resynchronization Therapy in Women Versus Men. Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes* 2015;8:4-11. doi: 10.1161/CIRCOUTCOMES.114.001548.
6. Cheng YJ, Zhang J, Li WJ, Lin XX, Zeng WT, Tang K, et al. More favorable response to cardiac resynchronization therapy in women than in men. *Circ Arrhythm Electrophysiol* 2014;7:807-815. doi: 10.1161/CIRCOUTCOMES.114.001548.
7. Biton Y, Zareba W, Goldenberg I, Klein H, Mcnitt S, Polonsky B, et al. Sex differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. *J Am Heart Assoc* 2015;4:1-7. doi: 10.1161/JAHA.115.002013.
8. Schuchert A, Muto C, Maoonis TH, Frank R, Rosa EO, Polauck A, et al. Gender-related safety and efficacy of cardiac resynchronization therapy. *Clin Cardiol* 2013;36(11):683–690. doi: 10.1002/clc22203.
9. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter Automatic Defillator Implantation Trial: cardiac resynchronization therapy. *Circulation* 2010;122:985-992. doi: 10.1161/CIRCULATIONAHA.110.959039.
10. Cheng A, Gold MR, Waggoner AD, Meyer TE, Seth M, Rapkin J, et al. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. *Heart Rhythm* 2012;9(5):736-741. doi: 10.1016/j.hrthm.2011.12.013.
11. Xu YZ, Friedman PA, Webster T, Brooke K, Hodge DO, Wiste HJ, et al. Cardiac resynchronization therapy: do women benefit more than men? *J Cardiovasc Electrophysiol* 2012;23:172-8. doi: 10.1111/j.1540-8167.2011.02168.x.
12. Mooyaart EA, Marsan NA, van Bommel RJ, Thijssen J, Borleffs Cj, Delgado V, et al. Comparison of long-term survival of men versus women with heart failure treated with cardiac resynchronization therapy. *Am J Cardiol* 2011;108:63-8. doi: 10.1016/j.amjcard.2011.02.345.
13. Dhruvu SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. *Circ Cardiovasc Qual Outcomes* 2011;4(2):165-71. doi: 10.1161/CIRCOUTCOMES.110.958215.
14. Zabarovskaja S, Gauder F, Braunschweig F, Stähberg M, Hörnsten J, Linde C, et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. * Europace* 2012;14:1148–155. doi: 10.1093/eurheartj/eus039.
15. Alaeddini J, Wood MA, Amin MS, Ellenbogen KA. Gender disparity in the use of cardiac resynchronization therapy in the United States. *Pacing Clin Electrophysiol* 2008;31:468–472. doi: 10.1111/j.1540-8159.2008.01016.x.
16. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004;350:2140-50. doi: 10.1056/NEJMoa032423.
17. Cleland JG, Daubert C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005;352:1539-49. doi: 10.1056/NEJMoa050496.
18. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory Cytokines in heart failure: mediators and markers. *Cardiology* 2012;122:23-35. doi: 10.1159/000338166.
19. Ducharme A, Franz S, Aikawa M, Rabbik E, Lindsay M, Robbe LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. *J Clin Invest* 2000;106(1):55–62. doi: 10.1172/JCI8768.
20. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege H. et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. *Clin Res Cardiol* 2010;99(5):323-28. doi: 10.1007/s00392-010-0125-y.
21. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. *Int J Cardiol* 182:168-70. doi: 10.1016/j.ijcard.2014.12.137.
22. Kuznetsov VA, Soldatova AM, Enina TN, Shebeko PV, Rychkov Ayu, Melnikov NN, et al. Biomarkers of inflammation in patients with chronic heart failure and implanted devices for cardiac resynchronization therapy. *Kardiologia* 2012;8:38-43.
23. Rordorf R, Savastano S, Sanzo A, Spazzolini C, De Amici M, Camponotondo R, et al. Tumor necrosis factor-α predicts response to cardiac resynchronization therapy in patients with chronic heart failure. *Circ J* 2014;78(9):2232-9.

24. Osmančík P, Herman D, Stros P, Linkova H, Vondrak K, Paskova E. Changes and prognostic impact of apoptotic and inflammatory cytokines in patients treated with cardiac resynchronization therapy. *Cardiology* 2013;124(3):190-8. doi: 10.1159/000346621.

25. Cai C, Hua W, Ding LG, Wang J, Chen KP, Yang XW, et al. High sensitivity C-reactive protein and cardiac resynchronization therapy in patients with advanced heart failure. *J Geriatr Cardiol* 2014;11:296-302. doi: 10.10909/jerationcardiol.2014.04.004.

26. Stanciu AE, Vataşescu RG, Stanciu MM, Iorgulescu C, Vasilie AI, Dorobantu M. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. *Clin Biochem* 2013;46(3):230-234. doi: 10.1016/j.clinbiochem.2012.11.002.

27. Mingjiang L, Yanli Z, Yongming Z, Kamesh B, Yueling W. Improvement in collagen metabolism after 12 weeks cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. *J Intern Med Res* 2013;41(1):200-7. doi: 10.1177/0300060513475757.

28. Tolosana JM, Mont L, Sitges M, Berruezo A, Delgado V, Vidal B, et al. Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy. *Eur J Heart Fail* 2010;12(5):492-8. doi: 10.1093/eurjhf/hfq037.

29. Stolen CM, Adourian A, Meyer TE, Stein KM, Solomon SD. Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). *J Card Fail* 2014;20(11):793-99. doi: 10.1016/j.cardfail.2014.07.018.29.

30. Lopez-Andrez N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dysynchrony: insights from CARE-HF (Cardiac Resynchronization therapy in Heart Failure). *Eur J Heart Fail* 2012;14:74-81. doi: 10.1093/eurjhf/hfr151.

31. Kuznetsov VA, Kolunin GV, Kh ratsa KE, Krinochkin DV, Rychkov AYu, Gorbunova TYu, et al. Register of the performed operations of cardiac resynchronization therapy. Certificate of state registration of database № 2010620077 of 1 February 2010.

32. Kuznetsov VA, Soldatova AM, Enina TN, Petelina TL. Natriuretic peptide and inflammation mediators in patients with different responses to cardiac resynchronization therapy. *Heart Fail* 2015;16(2):88-92.

33. Dong YX, Burnett JC, Chen HH, Sandberg S, Yang YZ, Zhang Y, et al. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure. *J Interv Card Electrophysiol* 2011;30(3):241-249. doi: 10.1007/s10840-011-9551-7.

34. Tarquini R, Guerra CT, Porciani MC, Michelucci A, Padeletti M, Riccardi G, et al. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure. *Cardiol J* 2009;16(6):545-52.

35. Berger R, Shankar A, Fruhwald F, Fahrleitner-Pammer A, Freimanel T, Tavazzi L, et al. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dysynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. *Eur Heart J* 2009;30(17):2109–16. doi: 10.1093/eurheartj/ehp210.

36. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, Biffi M, et al. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction response. *Peptides* 2006;27(7):1776-86. doi: 10.1016/j.peptides.2006.02.010.

37. Seifert M, Schlegl M, Hoersch W, Fleck E, Doelger A, Stockburger M, et al. Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. *Int J Cardiol* 2007;121(1):68-73. doi: 10.1016/j.ijcard.2007.04.069.

38. Orrego CM, Nasir N, Oliveira GH, Flores-Arredondo JH, Cordero-Reyes AM, Loebe M, et al. Cellular Evidence of Reverse Cardiac Remodeling Induced by Cardiac Resynchronization Therapy. *Congest Heart Fail* 2011;17:40–46. doi: 10.1111/j.1751-7133.2011.00227.x.

39. Tsai CT, Wu CK, Lee JK, Chang SN, Kuo YM, Wang YC, et al. TNF-α down-regulates sarcoplasmic reticulum Ca²⁺-ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-κB to promoter response element. *Cardiovasc Res* 2015;105(3):318-29. doi: 10.1093/cvr/crv008.

40. Dinh W, Füth R, Nickl W, Krahin T, Ellinghaus P, Scheffold T, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. *Cardiovasc Diabetol* 2009;8(8):58. doi: 10.1186/1475-2840-8-58.

41. Truong QA, Januzzi JL, Szymonińska J, Thai WE, Wai B, Lavender Z, et al. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRCT study. *Heart Rhythm* 2014;11(12):2167-75. doi: 10.1016/j.hrrthm.2014.07.007.

42. Siwicka DA, Chang DL-F, Colucci WS. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. *Circ Res* 2000;86(3):1259-1265.doi: 10.1161/01.RES.86.12.1259.

43. Corcoran M, Meydani M, Lichtenstein AH, Schaefer E, Dillard A, Lamon-Fava S. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. *J Endocrin* 2010;206:217-224. doi: 10.1677/JOE-10-0057.

44. Zhao Z, Wang H, Jessup JA, Lindsey SH, Chappell MC, Groban L. Role of estrogen in diastolic dysfunction. *Am J Physiol Heart Circ Physiol* 2014;306:H628-640. doi:10.1152/ajpheart.00859.2013.

45. Voloshenyuk TG, Gardner JD. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariecotomized females. *Am J Physiol Regul Integr Comp Physiol* 2010; 299(2):683-93. doi: 10.1152/ajpregu.01062.2010.

46. Ishikawa T, Harada T, Kubota T, Aso T. Testosterone inhibits matrix metalloproteinase-1 production in human endometrial stroma cells in vitro. *Reproduction* 2007;133(6):1233-1239. doi:10.1530/reprod.1.10089.